Design of Rhenium Compounds in Targeted Anticancer Therapeutics

Author:

Collery Philippe1ORCID,Desmaele Didier2ORCID,Vijaykumar Veena3ORCID

Affiliation:

1. Society for the Coordination of Therapeutic Researches, 20220 Algajola, France

2. Institut Galien, Universite Paris-Saclay, 92296 Chatenay-Malabry, France

3. Biotechnology Department, REVA University, Bangalore, 560064, India

Abstract

Background: Many rhenium (Re) complexes with potential anticancer properties have been synthesized in the recent years with the aim to overcome the clinical limitations of platinum agents. Re(I) tricarbonyl complexes are the most common but Re compounds with higher oxidation states have also been investigated, as well as hetero-metallic complexes and Re-loaded self-assembling devices. Many of these compounds display promising cytotoxic and phototoxic properties against malignant cells but all Re compounds are still at the stage of preclinical studies. Methods: The present review focused on the rhenium based cancer drugs that were in preclinical and clinical trials were examined critically. The detailed targeted interactions and experimental evidences of Re compounds reported by the patentable and non-patentable research findings used to write this review. Results: In the present review, we described the most recent and promising rhenium compounds focusing on their potential mechanism of action including, phototoxicity, DNA binding, mitochondrial effects, oxidative stress regulation or enzyme inhibition. Many ligands have been described that modulating the lipophilicity, the luminescent properties, the cellular uptake, the biodistribution, and the cytotoxicity, the pharmacological and toxicological profile. Conclusion: Re-based anticancer drugs can also be used in targeted therapies by coupling to a variety of biologically relevant targeting molecules. On the other hand, combination with conventional cytotoxic molecules, such as doxorubicin, allowed to take into profit the targeting properties of Re for example toward mitochondria. Through the example of the diseleno-Re complex, we showed that the main target could be the oxidative status, with a down-stream regulation of signaling pathways, and further on selective cell death of cancer cells versus normal cells.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference162 articles.

1. Collery P.; Poirier L.A.; Manfait M.; Etienne J.C.; Metal ions in biology and medicine 1990,600

2. Anastassopoulou J.; Collery P.; Etienne J.C.; Theophanides T.; Metal ions in biology and medicine 1992,453

3. Collery P.; Poirier L.; Littlefield N.; Etienne J.C.; Metal ions in biology and medicine 1994,585

4. Collery P.; Corbella J.; Domingo J.L.; Etienne J.C.; Llobet J.M.; Metal ions in biology and medicine 1996,703

5. Collery P.; Brätter P.; Negretti de Brätter V.; Khassanova L.; Etienne J.C.; Metal ions in biology and medicine 1998,775

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3